Curasight A/S is a clinical development company. It engages in the business of exploiting a novel theragnostic platform with positron emissions tomography imaging and radionuclide therapy targeting the urokinase-type plasminogen activator receptor. The company was founded by Morten Persson, Andreas Kjær, Carsten Haagen Nielsen, and Jacob Madsen in 2013 and is headquartered in Copenhagen, Denmark.